Regulatory Actions in May 2026: Key Updates for Pharma
Decision brief
Answer first · skim in under a minute
This article provides a comprehensive overview of the regulatory actions taken in May 2026, highlighting key updates and their implications for the pharmaceutical sector.
Regulatory actions in May 2026 delivered key updates for pharma across the Atlantic: the FDA logged three novel drug approvals mid-month, while EMA's CHMP recommended eight new medicines and 13 indication extensions. Access, labeling, and BD calendars need immediate recalibration.
Contents10 sections
Key Takeaways
- FDA novel approvals in May 2026: Veppanu (vepdegestrant, May 1), Beqalzi (sonrotoclax, May 13), and Baxfendy (baxdrostat, May 15).
- On May 8, 2026, FDA also approved zenocutuzumab-zbco (Bizengri) for NRG1 fusion–positive advanced cholangiocarcinoma after prior systemic therapy.
- CHMP's 18–21 May 2026 meeting issued eight positive opinions on new medicines and 13 extension recommendations, plus a negative opinion for Deqtynet.
- Oral Wegovy (semaglutide) tablet extension and Vijoice conditional authorisation for PROS were among the highest-visibility EU actions.
Which FDA novel approvals landed in May 2026?
According to the FDA Novel Drug Approvals for 2026 list, three May entries matter for portfolio planning:
- Veppanu (vepdegestrant), May 1, 2026 — ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy.
- Beqalzi (sonrotoclax), May 13, 2026 — adults with relapsed or refractory mantle cell lymphoma after at least two systemic lines including a BTK inhibitor.
- Baxfendy (baxdrostat), May 15, 2026 — hypertension in combination with other antihypertensive drugs.
These facts replace earlier unsourced claims about pediatric neurology, NSCLC, and heart-failure novel approvals that are not on the FDA May novel list.
What other FDA actions should teams track?
Beyond novel NMEs, FDA published a May 8, 2026 approval for zenocutuzumab-zbco (Bizengri) in adults with advanced, unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion after prior systemic therapy, per the FDA Zenocutuzumab approval notice.
That review used the Commissioner's National Priority Review Voucher pilot and Assessment Aid, and FDA said approval came more than five months ahead of the goal date.
What did EMA CHMP recommend in May 2026?
EMA's CHMP meeting highlights for 18–21 May 2026 (published 22 May 2026) record eight positive opinions on new medicines and 13 extensions of therapeutic indication.
- Jascayd (nerandomilast) for idiopathic or progressive pulmonary fibrosis.
- Vijoice (alpelisib) conditional authorisation for severe PIK3CA-related overgrowth spectrum (PROS).
- Etcamah (camizestrant) for ESR1-mutated locally advanced or metastatic breast cancer with a CDK4/6 inhibitor.
- Hybrid liraglutide products, Colchicine AGEPHA Pharma, and biosimilar Vislyfa (ranibizumab).
How should US–EU divergence shape launch strategy?
May actions show parallel but not identical ESR1 breast-cancer paths: FDA approved oral PROTAC vepdegestrant (Veppanu), while CHMP recommended camizestrant (Etcamah) with CDK4/6 inhibitors. Companies cannot copy-paste US labels into EU dossiers.
CHMP also recommended not authorising Deqtynet (copper (64Cu) oxodotreotide) for PET imaging of well-differentiated neuroendocrine tumours, and recorded withdrawals for Orblid (bevacizumab) and Veblocema (infliximab).
Which indication expansions matter commercially?
CHMP recommended extensions for 13 authorised medicines, including Enhertu, Keytruda, Trodelvy, Padcev, Fasenra, and Braftovi. Separately, CHMP recommended adding a daily oral Wegovy tablet as an alternative to weekly subcutaneous semaglutide for weight management in adults with obesity or overweight plus comorbidity—the first oral GLP-1 for that use, per EMA.
FDA May coverage also included interchangeable golimumab biosimilars and additional oncology label work; teams should verify each product-specific FDA notice before updating formulary decks.
What remains unproven after May announcements?
FDA novel listings and CHMP opinions document agency decisions and recommendations. They do not prove real-world uptake, reimbursement timing, manufacturing scale-up, or that every pending EC decision will follow the CHMP vote without change. Market-access models still need payer evidence beyond the regulatory headline.
Related NovaPharma coverage
- Life Sciences Dealmaking Gains Strategic Momentum
- Vabysmo EU Approval for Retinal Vein Occlusion
- PRAC Meeting Highlights: May 2026 Regulatory Updates
Frequently Asked Questions
Which novel FDA drugs were approved in May 2026?
FDA's 2026 novel drug list records May approvals for Veppanu (vepdegestrant) on May 1, Beqalzi (sonrotoclax) on May 13, and Baxfendy (baxdrostat) on May 15, covering ESR1-mutated breast cancer, relapsed or refractory mantle cell lymphoma, and hypertension, respectively.
What did EMA's May 2026 CHMP meeting recommend?
At its 18–21 May 2026 meeting, CHMP recommended eight medicines for approval and 13 extensions of indication, including positive opinions for Jascayd (nerandomilast), Vijoice (alpelisib), Etcamah (camizestrant), and an oral Wegovy tablet extension.
Do CHMP positive opinions equal EU marketing authorisation?
No. CHMP opinions are recommendations; European Commission marketing authorisation is still required before EU launch, and FDA approvals do not automatically translate into EU labels.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
